Aggressive astrocytomas

A Swiss-led research initiative is developing nanozymes to treat aggressive astrocytomas, targeting a cancer with a five-year survival rate of only 5%. By applying bio-compatible nanomaterials directly during surgery and activating them with near-infrared light, researchers aim to bypass the …